Cell Based Assays Market - Global Forecast to 2029
商品番号 : SMB-36389
出版社 | MarketsandMarkets |
出版年月 | 2025年4月 |
ページ数 | 449 |
図表数 | 624 |
価格タイプ | シングルユーザライセンス |
価格 | USD 4,950 |
種別 | 英文調査報告書 |
この調査レポートでは、セルベースアッセイ(細胞ベースアッセイ)市場を{消耗品[試薬、アッセイキット(レポーター遺伝子アッセイ、細胞増殖アッセイ、二次メッセンジャーアッセイ、細胞死アッセイ、その他のアッセイキット)、マイクロプレート、細胞株(不死化細胞株、初代細胞株、幹細胞株)、プローブとラベル、その他の消耗品]、機器、ソフトウェア、サービス}、技術(フローサイトメトリー、ハイスループットスクリーニング、ラベルフリー検出、その他の技術)、用途[創薬(毒物学、薬力学、薬物動態学)、基礎研究、遺伝子研究、その他の用途]、エンドユーザー(製薬およびバイオ製薬会社、受託研究機関(CRO)、学術研究機関)、および地域(北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ)に分類しています。本レポートは、細胞ベースアッセイ市場の成長に影響を与える主要な要因(促進要因、制約要因、課題、機会など)に関する詳細な情報を網羅しています。業界の主要プレーヤーを包括的に分析し、各社の事業概要、製品、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。また、新製品の発売、提携、買収、そして細胞ベースアッセイ市場に関連する最近の動向に関する情報も含まれています。
Report Overview
The cell-based assays market is projected to reach USD 27.55 billion by 2030 from an estimated USD 17.84 billion in 2025, at a CAGR of 9.1% during the forecast period from 2025 to 2030. This growth can be largely attributed to the increasing demand for drug discovery and the rising need for cell-based assays in this area. Furthermore, higher research & development investments from the pharmaceutical and biotechnology industries are driving the growth of the cell-based assays market. Additionally, the growing incidence of cancer is increasing the demand for advanced therapies, which further boosts market expansion. The expanding applications of cell-based assays in chronic diseases and personalized medicine are also expected to propel market growth in the coming years.
セルベースアッセイ市場は、2025年の推定178億4,000万米ドルから2030年には275億5,000万米ドルに達すると予測されており、2025年から2030年の予測期間中、年平均成長率(CAGR)9.1%で成長します。この成長は、主に創薬需要の増加と、この分野における細胞ベースアッセイの需要の高まりに起因しています。さらに、製薬業界およびバイオテクノロジー業界による研究開発投資の増加も、細胞ベースアッセイ市場の成長を牽引しています。さらに、がんの発生率増加に伴い、先進的な治療法への需要が高まっており、市場拡大をさらに後押ししています。慢性疾患や個別化医療における細胞ベースアッセイの用途拡大も、今後数年間の市場成長を牽引すると予想されます。

“The drug discovery segment accounted for the largest share of the application segment in 2024.”
The cell-based assays market is segmented by application into drug discovery, basic research, genetic studies, and other applications. The drug discovery segment is further categorized into toxicity, pharmacokinetic, and pharmacodynamic studies. In 2024, the drug discovery segment accounted for the largest share of the global cell-based assays market. The increasing prevalence of cancer is driving the demand for advanced therapies, which, in turn, promotes the growth of this segment within the cell-based assays market. Additionally, rising investments in research and development, the introduction of new drugs, and a growing number of contract research organizations offering drug discovery services to pharmaceutical and biotechnology companies are also expected to contribute to the segment’s continued growth in the cell-based assays market.
“The flow cytometry segment accounted for a major share of the technology market in 2024.”
The cell-based assays market is categorized by technology into flow cytometry, high-throughput screening, label-free detection, and other technologies. In 2024, flow cytometry held the largest share of the global cell-based assays market within this category. The growth of the flow cytometry segment is primarily due to its widespread use in cell-based assays, allowing for multiple measurements. Additionally, the increasing adoption of advanced technologies for cell analysis and characterization is expected to further enhance the growth of this segment in the cell-based assays market.

“The US dominated the cell-based assays market in 2024.”
The cell-based assays market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, the US dominated the cell-based assays market in North America. As the largest biopharmaceutical market in the world, the US leads in biopharmaceutical research and investments. The country also boasts a robust healthcare infrastructure that supports research and development in the life sciences sector.
Additionally, the significant presence of numerous biopharmaceutical companies and increased research activities in the biotechnology industry are driving market growth in the US. Furthermore, the rising emphasis on developing advanced cell-based therapies, prompted by the increasing incidence of cancer, contributes to the growth of the cell-based assays market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (60%) and Demand Side (40%)
- By Designation: Managers (45%), CXOs & Directors (30%0, and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
List of Companies Profiled in the Report:
- BD (US)
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (US)
- Lonza (Switzerland)
- Charles River Laboratories (US)
- Bio-Rad Laboratories, Inc. (US)
- REVVITY (US)
- Sartorius AG (Germany)
- Corning Incorporated (US)
- Promega Corporation (US)
- Cell Signaling Technology, Inc. (US)
- Eurofins Scientific (Luxembourg)
- Enzo Biochem, Inc. (US)
- Carna Biosciences, Inc. (Japan)
- Intertek Group Plc (UK)
- BICO (Sweden)
- Cell Biolabs, Inc. (US)
- Reaction Biology (US)
- AAT Bioquest, Inc. (US)
- Pestka Biomedical Laboratories, Inc. (US)
- Neuromics (US)
- BPS Bioscience, Inc. (US)
- BellBrook Labs (US)
- Profacgen (US)
- BMG LABTECH (Germany)
- Hanugen Therapeutics (India)
- Altogen Labs (US)
- BioAgilytix (US)

Research Coverage:
This research report categorizes the cell-based assays market by offering {consumables [reagents, assay kits (reporter gene assays, cell growth assays, secondary messenger assays, cell death assays, and other assay kits), microplates, cell lines (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables], instruments, software, and services}, technology (flow cytometry, high-throughput screening, label-free detection, and other technologies), application [drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications], end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This analysis also includes information about new product launches, collaborations, acquisitions, and recent developments related to the cell-based assays market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, a surge in cases of cancer, and increasing R&D investments and funding for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market.
- Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), REVVITY (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group Plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), Altogen Labs (US), and BioAgilytix (US).
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 INCLUSIONS & EXCLUSIONS 39
1.3.2 MARKET SEGMENTATION AND REGIONAL SCOPE 40
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.2 PRIMARY DATA 45
2.2 MARKET SIZE ESTIMATION 46
2.2.1 GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH) 46
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 48
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 49
2.3 MARKET GROWTH RATE PROJECTIONS 50
2.4 DATA TRIANGULATION 52
2.5 RESEARCH ASSUMPTIONS 52
2.6 RISK ANALYSIS 53
2.7 RESEARCH LIMITATIONS 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 59
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CELL-BASED ASSAYS MARKET 59
4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2024) 60
4.3 CELL-BASED ASSAYS MARKET, BY OFFERING, 2024 60
4.4 CELL-BASED ASSAYS MARKET, BY END USER, 2024 61
4.5 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 64
5.2.1.1 Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery 64
5.2.1.2 Government support and funding for cell-based research 65
5.2.1.3 Growing efforts to curtail animal-based studies 66
5.2.1.4 Rising prevalence of cancer 66
5.2.1.5 Alliances to accelerate innovations in drug discovery 68
5.2.2 RESTRAINTS 69
5.2.2.1 High cost of instruments and restrictions imposed by product
end-user licenses for reagents 69
5.2.2.2 Lack of standardization of protocols used in cell-based assays 69
5.2.3 OPPORTUNITIES 70
5.2.3.1 Growing applications of cell-based assays in chronic diseases and personalized medicine 70
5.2.3.2 Growth opportunities in emerging economies 71
5.2.3.3 Rising adoption of AI in drug discovery and cell analysis 72
5.2.4 CHALLENGES 73
5.2.4.1 Complexities in assay designs 73
5.2.4.2 Shortage of skilled professionals 73
5.3 TECHNOLOGY ANALYSIS 73
5.3.1 KEY TECHNOLOGIES 73
5.3.1.1 Flow cytometry 73
5.3.1.2 High-throughput screening 74
5.3.1.3 High-content screening 74
5.3.1.4 Label-free detection 75
5.3.2 COMPLEMENTARY TECHNOLOGIES 75
5.3.2.1 Artificial intelligence and machine learning 75
5.3.3 ADJACENT TECHNOLOGIES 76
5.3.3.1 Nanotechnology 76
5.4 VALUE CHAIN ANALYSIS 76
5.5 PRICING ANALYSIS 78
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS,
BY PRODUCT, 2021–2024 79
5.5.2 AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024 80
5.6 ECOSYSTEM ANALYSIS 80
5.6.1 RAW MATERIAL VENDORS 81
5.6.2 PRODUCT/SERVICE VENDORS 81
5.6.3 END USERS 82
5.6.4 REGULATORY BODIES 82
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 83
5.8 PATENT ANALYSIS 83
5.8.1 NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE,
2014–2025 84
5.9 KEY CONFERENCES & EVENTS, 2025–2026 86
5.10 TARIFF AND REGULATORY LANDSCAPE 86
5.10.1 TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS 86
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
5.10.3 REGULATORY FRAMEWORK 90
5.10.3.1 North America 90
5.10.3.2 Europe 90
5.10.3.3 Asia Pacific 90
5.10.3.4 Rest of the World 91
5.11 PORTER’S FIVE FORCES ANALYSIS 92
5.11.1 THREAT OF NEW ENTRANTS 93
5.11.2 THREAT OF SUBSTITUTES 93
5.11.3 BARGAINING POWER OF SUPPLIERS 93
5.11.4 BARGAINING POWER OF BUYERS 93
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 93
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 94
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 94
5.12.2 BUYING CRITERIA 95
5.13 INVESTMENT AND FUNDING SCENARIO 96
5.14 TRADE ANALYSIS 97
5.14.1 IMPORT DATA 97
5.14.2 EXPORT DATA 99
5.15 IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET 100
5.16 IMPACT OF 2025 US TARIFF ON CELL-BASED ASSAYS MARKET 102
5.16.1 INTRODUCTION 102
5.16.2 KEY TARIFF RATES 102
5.16.3 PRICE IMPACT ANALYSIS 103
5.16.4 IMPACT ON COUNTRY/REGION 104
5.16.4.1 US 104
5.16.4.2 Europe 104
5.16.4.3 Asia Pacific 104
5.16.5 IMPACT ON END-USE INDUSTRIES 105
5.16.5.1 Pharmaceutical & biotech companies 105
5.16.5.2 Contract research organizations (CROs) 106
5.16.5.3 Academic & research institutes 106
6 CELL-BASED ASSAYS MARKET, BY OFFERING 107
6.1 INTRODUCTION 108
6.2 CONSUMABLES 108
6.2.1 REAGENTS 113
6.2.1.1 High demand for reagents in research applications to
propel market growth 113
6.2.2 ASSAY KITS 116
6.2.2.1 Reporter gene assays 120
6.2.2.1.1 Versatility of reporter gene assays and widespread applications to fuel growth 120
6.2.2.2 Cell growth assays 124
6.2.2.2.1 Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market 124
6.2.2.3 Secondary messenger assays 128
6.2.2.3.1 Adoption of secondary messenger assays for cell signaling studies to fuel growth 128
6.2.2.4 Cell death assays 132
6.2.2.4.1 Importance of cell death quantification in drug development to favor growth 132
6.2.2.5 Other assay kits 135
6.2.3 MICROPLATES 138
6.2.3.1 Demand for microplates in assay development to drive market 138
6.2.4 CELL LINES 141
6.2.4.1 Immortalized cell lines 144
6.2.4.1.1 Wide use of immortalized cell lines to boost market 144
6.2.4.2 Primary cell lines 147
6.2.4.2.1 Advantages in drug development, preclinical research, and other applications to propel market 147
6.2.4.3 Stem cell lines 151
6.2.4.3.1 Rising use in tissue and disease models to fuel adoption 151
6.2.5 PROBES & LABELS 154
6.2.5.1 Growing need for effective cell labeling to boost demand 154
6.2.6 OTHER CONSUMABLES 158
6.3 INSTRUMENTS 161
6.3.1 AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH 161
6.4 SERVICES 165
6.4.1 GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH 165
6.5 SOFTWARE 168
6.5.1 INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS
TO DRIVE GROWTH 168
7 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY 171
7.1 INTRODUCTION 172
7.2 FLOW CYTOMETRY 172
7.2.1 WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO
DRIVE MARKET 172
7.3 HIGH-THROUGHPUT SCREENING 176
7.3.1 INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH 176
7.4 LABEL-FREE DETECTION 179
7.4.1 GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND 179
7.5 OTHER TECHNOLOGIES 183
8 CELL-BASED ASSAYS MARKET, BY APPLICATION 186
8.1 INTRODUCTION 187
8.2 DRUG DISCOVERY 187
8.2.1 TOXICITY STUDIES 191
8.2.1.1 Increasing demand for cell-based assays in toxicity testing to
fuel growth 191
8.2.2 PHARMACOKINETIC STUDIES 195
8.2.2.1 Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays 195
8.2.3 PHARMACODYNAMIC STUDIES 199
8.2.3.1 Advantages of cell-based assays in pharmacodynamics to
propel growth 199
8.3 BASIC RESEARCH 203
8.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES 203
8.4 GENETIC STUDIES 207
8.4.1 INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET 207
8.5 OTHER APPLICATIONS 210
9 CELL-BASED ASSAYS MARKET, BY END USER 214
9.1 INTRODUCTION 215
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 215
9.2.1 GROWTH IN R&D EFFORTS TOWARD CELL-BASED ASSAYS IN PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTORS TO DRIVE MARKET 215
9.3 CONTRACT RESEARCH ORGANIZATIONS 220
9.3.1 GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR
CELL-BASED ASSAYS IN CONTRACT RESEARCH 220
9.4 ACADEMIC & RESEARCH INSTITUTES 224
9.4.1 RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS
TO DRIVE MARKET 224
10 CELL-BASED ASSAYS MARKET, BY REGION 228
10.1 INTRODUCTION 229
10.2 NORTH AMERICA 229
10.2.1 MACROECONOMIC OUTLOOK 230
10.2.2 US 235
10.2.2.1 Established pharmaceutical and biotechnology sectors to
drive market 235
10.2.3 CANADA 239
10.2.3.1 Increasing funding and investments to drive market 239
10.3 EUROPE 242
10.3.1 MACROECONOMIC OUTLOOK 242
10.3.2 GERMANY 246
10.3.2.1 To dominate cell-based assays market in Europe 246
10.3.3 UK 250
10.3.3.1 Growing cancer research funding to increase demand for
cell-based assays 250
10.3.4 FRANCE 254
10.3.4.1 Growing biotechnology sector to drive market 254
10.3.5 ITALY 258
10.3.5.1 Growth of pharmaceutical industry to boost market 258
10.3.6 SPAIN 261
10.3.6.1 Rising research activity and increasing number of biotech companies to favor market growth 261
10.3.7 REST OF EUROPE 264
10.4 ASIA PACIFIC 267
10.4.1 MACROECONOMIC OUTLOOK 268
10.4.2 CHINA 273
10.4.2.1 Increasing R&D expenditure to favor market growth 273
10.4.3 JAPAN 277
10.4.3.1 Government initiatives for drug innovation to support market growth 277
10.4.4 INDIA 280
10.4.4.1 Increasing investments in R&D and funding for life science research to propel market 280
10.4.5 AUSTRALIA 284
10.4.5.1 Booming life science sector to propel market 284
10.4.6 SOUTH KOREA 287
10.4.6.1 Increasing strategic alliances to support market growth 287
10.4.7 REST OF ASIA PACIFIC 290
10.5 LATIN AMERICA 294
10.5.1 MACROECONOMIC OUTLOOK 294
10.5.2 BRAZIL 298
10.5.2.1 Brazil to hold largest share of Latin American market 298
10.5.3 MEXICO 302
10.5.3.1 Government support for biopharmaceutical production to
support market growth 302
10.5.4 REST OF LATIN AMERICA 305
10.6 MIDDLE EAST 308
10.6.1 MACROECONOMIC OUTLOOK 308
10.6.2 GCC COUNTRIES 312
10.6.2.1 Saudi Arabia 315
10.6.2.1.1 Increasing R&D investments to drive market 315
10.6.2.2 UAE 319
10.6.2.2.1 Investments and support for biopharma sector to offer growth opportunities 319
10.6.2.3 Rest of GCC Countries 322
10.6.3 REST OF MIDDLE EAST 325
10.7 AFRICA 329
10.7.1 RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH 329
10.7.2 MACROECONOMIC OUTLOOK 329
11 COMPETITIVE LANDSCAPE 333
11.1 OVERVIEW 333
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025 333
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN
CELL-BASED ASSAYS MARKET 334
11.3 REVENUE ANALYSIS, 2020–2024 336
11.4 MARKET SHARE ANALYSIS, 2024 337
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 339
11.5.1 STARS 339
11.5.2 EMERGING LEADERS 340
11.5.3 PERVASIVE PLAYERS 340
11.5.4 PARTICIPANTS 340
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 342
11.5.5.1 Company footprint 342
11.5.5.2 Offering footprint 343
11.5.5.3 Technology footprint 344
11.5.5.4 Application Footprint 345
11.5.5.5 Region footprint 346
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 347
11.6.1 PROGRESSIVE COMPANIES 347
11.6.2 RESPONSIVE COMPANIES 347
11.6.3 DYNAMIC COMPANIES 347
11.6.4 STARTING BLOCKS 347
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 349
11.6.5.1 Detailed list of key startups/SMEs 349
11.6.5.2 Competitive benchmarking of key emerging players/startups 351
11.7 COMPANY VALUATION & FINANCIAL METRICS 352
11.8 BRAND/PRODUCT COMPARISON 353
11.9 COMPETITIVE SCENARIO 354
11.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 354
11.9.2 DEALS 355
11.9.3 EXPANSIONS 356
12 COMPANY PROFILES 357
12.1 INTRODUCTION 357
12.2 KEY PLAYERS 357
12.2.1 DANAHER 357
12.2.1.1 Business overview 357
12.2.1.2 Products/Services offered 359
12.2.1.3 Recent developments 361
12.2.1.3.1 Deals 361
12.2.1.3.2 Expansions 362
12.2.1.4 MnM view 362
12.2.1.4.1 Key strengths 362
12.2.1.4.2 Strategic choices 362
12.2.1.4.3 Weaknesses & competitive threats 362
12.2.2 THERMO FISHER SCIENTIFIC INC. 363
12.2.2.1 Business overview 363
12.2.2.2 Products/Services offered 364
12.2.2.3 Recent developments 368
12.2.2.3.1 Deals 368
12.2.2.3.2 Expansions 369
12.2.2.3.3 Other developments 369
12.2.2.4 MnM view 369
12.2.2.4.1 Key strengths 369
12.2.2.4.2 Strategic choices 370
12.2.2.4.3 Weaknesses & competitive threats 370
12.2.3 MERCK KGAA 371
12.2.3.1 Business overview 371
12.2.3.2 Products/Services offered 372
12.2.3.3 Recent developments 375
12.2.3.3.1 Deals 375
12.2.3.3.2 Expansions 375
12.2.3.4 MnM view 376
12.2.3.4.1 Key strengths 376
12.2.3.4.2 Strategic choices 376
12.2.3.4.3 Weaknesses & competitive threats 376
12.2.4 BD 377
12.2.4.1 Business overview 377
12.2.4.2 Products/Services offered 378
12.2.4.3 Recent developments 381
12.2.4.3.1 Product launches 381
12.2.4.3.2 Deals 381
12.2.4.4 MnM view 382
12.2.4.4.1 Key strengths 382
12.2.4.4.2 Strategic choices 382
12.2.4.4.3 Weaknesses & competitive threats 382
12.2.5 AGILENT TECHNOLOGIES, INC. 383
12.2.5.1 Business overview 383
12.2.5.2 Products/Services offered 384
12.2.5.3 Recent developments 385
12.2.5.3.1 Product launches 385
12.2.5.4 MnM view 385
12.2.5.4.1 Key strengths 385
12.2.5.4.2 Strategic choices 386
12.2.5.4.3 Weaknesses & competitive threats 386
12.2.6 LONZA 387
12.2.6.1 Business overview 387
12.2.6.2 Products/Services offered 388
12.2.6.3 Recent developments 389
12.2.6.3.1 Deals 389
12.2.6.3.2 Expansions 389
12.2.7 EUROFINS SCIENTIFIC 390
12.2.7.1 Business overview 390
12.2.7.2 Products/Services offered 391
12.2.7.3 Recent developments 393
12.2.7.3.1 Deals 393
12.2.8 CHARLES RIVER LABORATORIES 394
12.2.8.1 Business overview 394
12.2.8.2 Products/services offered 395
12.2.8.3 Recent developments 397
12.2.8.3.1 Service launches 397
12.2.8.3.2 Deals 397
12.2.9 BIO-RAD LABORATORIES, INC. 399
12.2.9.1 Business overview 399
12.2.9.2 Products/Services offered 400
12.2.10 REVVITY 402
12.2.10.1 Business overview 402
12.2.10.2 Products/Services offered 403
12.2.10.3 Recent developments 405
12.2.10.3.1 Product launches 405
12.2.11 SARTORIUS AG 406
12.2.11.1 Business overview 406
12.2.11.2 Products/Services offered 408
12.2.11.3 Recent developments 408
12.2.11.3.1 Expansions 408
12.2.12 CORNING INCORPORATED 409
12.2.12.1 Business overview 409
12.2.12.2 Products/Services offered 410
12.2.13 PROMEGA CORPORATION 412
12.2.13.1 Business overview 412
12.2.13.2 Products/Services offered 412
12.2.13.3 Recent developments 413
12.2.13.3.1 Product launches 413
12.2.14 CELL SIGNALING TECHNOLOGY, INC. 414
12.2.14.1 Business overview 414
12.2.14.2 Products/Services offered 414
12.2.15 ENZO BIOCHEM INC. 416
12.2.15.1 Business overview 416
12.2.15.2 Products/Services offered 417
12.2.15.3 Recent developments 419
12.2.15.3.1 Expansions 419
12.2.16 CARNA BIOSCIENCES, INC. 420
12.2.16.1 Business overview 420
12.2.16.2 Products/Services offered 421
12.2.17 INTERTEK GROUP PLC 423
12.2.17.1 Business overview 423
12.2.17.2 Products/services offered 424
12.2.17.3 Recent developments 425
12.2.17.3.1 Expansions 425
12.2.18 BICO 426
12.2.18.1 Business overview 426
12.2.18.2 Products/Services offered 427
12.3 OTHER PLAYERS 428
12.3.1 CELL BIOLABS, INC. 428
12.3.2 REACTION BIOLOGY 429
12.3.3 AAT BIOQUEST, INC. 430
12.3.4 PESTKA BIOMEDICAL LABORATORIES, INC. 432
12.3.5 NEUROMICS 433
12.3.6 BPS BIOSCIENCE, INC. 433
12.3.7 BELLBROOK LABS 435
12.3.8 PROFACGEN 436
12.3.9 BMG LABTECH GMBH 436
12.3.10 HANUGEN THERAPEUTICS 437
12.3.11 ALTOGEN LABS 438
12.3.12 BIOAGILYTIX LABS 439
13 APPENDIX 440
13.1 DISCUSSION GUIDE 440
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 445
13.3 CUSTOMIZATION OPTIONS 447
13.4 RELATED REPORTS 447
13.5 AUTHOR DETAILS 448
LIST OF TABLES
TABLE 1 CELL-BASED ASSAYS MARKET: INCLUSIONS AND EXCLUSIONS 39
TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 51
TABLE 3 CELL-BASED ASSAYS MARKET: IMPACT ANALYSIS 63
TABLE 4 ESTIMATED EXPENDITURE BY US NIH FOR STEM CELL RESEARCH, 2019–2025 65
TABLE 5 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2022 VS. 2045 66
TABLE 6 CELL-BASED ASSAYS MARKET: KEY DEVELOPMENTS 68
TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021–2024 79
TABLE 8 AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024 80
TABLE 9 CELL-BASED ASSAYS MARKET: ROLE OF RAW MATERIAL VENDORS 81
TABLE 10 CELL-BASED ASSAYS MARKET: ROLE OF PRODUCT/SERVICE VENDORS 81
TABLE 11 CELL-BASED ASSAYS MARKET: ROLE OF END USERS 82
TABLE 12 CELL-BASED ASSAYS MARKET: ROLE OF REGULATORY BODIES 82
TABLE 13 NUMBER OF PATENTS APPLIED AND GRANTED, JANUARY 2014–APRIL 2025 84
TABLE 14 INNOVATIONS AND PATENT REGISTRATIONS, 2025 85
TABLE 15 CELL-BASED ASSAYS MARKET: LIST OF KEY CONFERENCES & EVENTS,
2025–2026 86
TABLE 16 AVERAGE TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS FOR
HS CODE 9027, 2024 86
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 88
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 89
TABLE 21 CELL-BASED ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS 92
TABLE 22 BUYING CRITERIA FOR CELL-BASED ASSAY PRODUCTS, BY END USER 95
TABLE 23 IMPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES),
2020–2024 (USD THOUSAND) 97
TABLE 24 IMPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (TONS) 98
TABLE 25 EXPORT VALUE FOR HS CODE 9027 (TOP 20 COUNTRIES),
2020–2024 (USD THOUSAND) 99
TABLE 26 EXPORT VOLUME FOR HS CODE 9027 (TOP 20 COUNTRIES), 2020–2024 (TONS) 100
TABLE 27 US ADJUSTED RECIPROCAL TARIFF RATES 102
TABLE 28 CELL-BASED ASSAY PRODUCTS-RELATED TARIFF REVISION 103
TABLE 29 IMPACT ON END-USE APPLICATIONS OF CELL-BASED ASSAY PRODUCTS 105
TABLE 30 CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 108
TABLE 31 CONSUMABLES OFFERED BY KEY COMPANIES 109
TABLE 32 CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 110
TABLE 33 CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 34 NORTH AMERICA: CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 35 EUROPE: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 36 ASIA PACIFIC: CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 37 LATIN AMERICA: CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 38 MIDDLE EAST: CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 112
TABLE 39 GCC COUNTRIES: CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 112
TABLE 40 REAGENTS OFFERED BY KEY COMPANIES 113
TABLE 41 REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 42 NORTH AMERICA: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 43 EUROPE: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 44 ASIA PACIFIC: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 45 LATIN AMERICA: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 46 MIDDLE EAST: REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 47 GCC COUNTRIES: REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 48 ASSAY KITS OFFERED BY KEY COMPANIES 117
TABLE 49 ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 117
TABLE 50 ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 118
TABLE 51 NORTH AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 52 EUROPE: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 53 ASIA PACIFIC: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 54 LATIN AMERICA: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 55 MIDDLE EAST: ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 56 GCC COUNTRIES: ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 57 REPORTER GENE ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION) 121
TABLE 58 NORTH AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 121
TABLE 59 EUROPE: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 60 ASIA PACIFIC: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 122
TABLE 61 LATIN AMERICA: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 123
TABLE 62 MIDDLE EAST: REPORTER GENE ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 123
TABLE 63 GCC COUNTRIES: REPORTER GENE ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 123
TABLE 64 CELL GROWTH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 65 NORTH AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 125
TABLE 66 EUROPE: CELL GROWTH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 67 ASIA PACIFIC: CELL GROWTH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 68 LATIN AMERICA: CELL GROWTH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 69 MIDDLE EAST: CELL GROWTH ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 127
TABLE 70 GCC COUNTRIES: CELL GROWTH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 71 SECONDARY MESSENGER ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 129
TABLE 72 NORTH AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 73 EUROPE: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 74 ASIA PACIFIC: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 130
TABLE 75 LATIN AMERICA: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 131
TABLE 76 MIDDLE EAST: SECONDARY MESSENGER ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 131
TABLE 77 GCC COUNTRIES: SECONDARY MESSENGER ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 78 CELL DEATH ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 79 NORTH AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 133
TABLE 80 EUROPE: CELL DEATH ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 81 ASIA PACIFIC: CELL DEATH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 133
TABLE 82 LATIN AMERICA: CELL DEATH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 83 MIDDLE EAST: CELL DEATH ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 134
TABLE 84 GCC COUNTRIES: CELL DEATH ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 134
TABLE 85 OTHER ASSAY KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 86 NORTH AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 135
TABLE 87 EUROPE: OTHER ASSAY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 88 ASIA PACIFIC: OTHER ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 136
TABLE 89 LATIN AMERICA: OTHER ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 90 MIDDLE EAST: OTHER ASSAY KITS MARKET, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 91 GCC COUNTRIES: OTHER ASSAY KITS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 92 MICROPLATES MARKET, BY REGION, 2023–2030 (USD MILLION) 138
TABLE 93 NORTH AMERICA: MICROPLATES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 139
TABLE 94 EUROPE: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 95 ASIA PACIFIC: MICROPLATES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 96 LATIN AMERICA: MICROPLATES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 97 MIDDLE EAST: MICROPLATES MARKET, BY REGION, 2023–2030 (USD MILLION) 140
TABLE 98 GCC COUNTRIES: MICROPLATES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 99 CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 100 CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION) 142
TABLE 101 NORTH AMERICA: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 102 EUROPE: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 103 ASIA PACIFIC: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 104 LATIN AMERICA: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 105 MIDDLE EAST: CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION) 143
TABLE 106 GCC COUNTRIES: CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 107 IMMORTALIZED CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION) 145
TABLE 108 NORTH AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 109 EUROPE: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 145
TABLE 110 ASIA PACIFIC: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 146
TABLE 111 LATIN AMERICA: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 146
TABLE 112 MIDDLE EAST: IMMORTALIZED CELL LINES MARKET, BY REGION,
2023–2030 (USD MILLION) 146
TABLE 113 GCC COUNTRIES: IMMORTALIZED CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 114 PRIMARY CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION) 148
TABLE 115 NORTH AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 116 EUROPE: PRIMARY CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 149
TABLE 117 ASIA PACIFIC: PRIMARY CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 149
TABLE 118 LATIN AMERICA: PRIMARY CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 119 MIDDLE EAST: PRIMARY CELL LINES MARKET, BY REGION,
2023–2030 (USD MILLION) 150
TABLE 120 GCC COUNTRIES: PRIMARY CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 121 STEM CELL LINES MARKET, BY REGION, 2023–2030 (USD MILLION) 152
TABLE 122 NORTH AMERICA: STEM CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 123 EUROPE: STEM CELL LINES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 124 ASIA PACIFIC: STEM CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 125 LATIN AMERICA: STEM CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 126 MIDDLE EAST: STEM CELL LINES MARKET, BY REGION,
2023–2030 (USD MILLION) 153
TABLE 127 GCC COUNTRIES: STEM CELL LINES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 154
TABLE 128 PROBES & LABELS MARKET, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 129 NORTH AMERICA: PROBES & LABELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 155
TABLE 130 EUROPE: PROBES & LABELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 131 ASIA PACIFIC: PROBES & LABELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 132 LATIN AMERICA: PROBES & LABELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 133 MIDDLE EAST: PROBES & LABELS MARKET, BY REGION,
2023–2030 (USD MILLION) 157
TABLE 134 GCC COUNTRIES: PROBES & LABELS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 135 OTHER CONSUMABLES OFFERED BY KEY COMPANIES 158
TABLE 136 OTHER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION) 158
TABLE 137 NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 138 EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 139 ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 159
TABLE 140 LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 160
TABLE 141 MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION,
2023–2030 (USD MILLION) 160
TABLE 142 GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 160
TABLE 143 INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 144 NORTH AMERICA: INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 145 EUROPE: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 146 ASIA PACIFIC: INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 163
TABLE 147 LATIN AMERICA: INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 148 MIDDLE EAST: INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 164
TABLE 149 GCC COUNTRIES: INSTRUMENTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 150 SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 165
TABLE 151 NORTH AMERICA: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 152 EUROPE: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 153 ASIA PACIFIC: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 154 LATIN AMERICA: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 155 MIDDLE EAST: SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 167
TABLE 156 GCC COUNTRIES: SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 157 SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 168
TABLE 158 NORTH AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 159 EUROPE: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 160 ASIA PACIFIC: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 161 LATIN AMERICA: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 162 MIDDLE EAST: SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 170
TABLE 163 GCC COUNTRIES: SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 164 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 172
TABLE 165 CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION,
2023–2030 (USD MILLION) 173
TABLE 166 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 167 EUROPE: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 168 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 169 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 170 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 171 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR FLOW CYTOMETRY,
BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 172 CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 173 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 174 EUROPE: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING,
BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 175 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 176 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 177 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 178 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 179 CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION, BY REGION,
2023–2030 (USD MILLION) 180
TABLE 180 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 181 EUROPE: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 182 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 183 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 184 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,
BY REGION, 2023–2030 (USD MILLION) 182
TABLE 185 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR LABEL-FREE DETECTION,
BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 186 OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 183
TABLE 187 NORTH AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 188 EUROPE: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 189 ASIA PACIFIC: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 190 LATIN AMERICA: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 191 MIDDLE EAST: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 192 GCC COUNTRIES: OTHER CELL-BASED ASSAY TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 193 CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 194 CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 195 CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 188
TABLE 196 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 197 EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 198 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 199 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 200 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 191
TABLE 201 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 202 CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION,
2023–2030 (USD MILLION) 192
TABLE 203 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 204 EUROPE: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 205 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 206 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 207 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES, BY REGION, 2023–2030 (USD MILLION) 195
TABLE 208 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR TOXICITY STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 209 CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY REGION, 2023–2030 (USD MILLION) 196
TABLE 210 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 211 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 212 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 213 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 214 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES,
BY REGION, 2023–2030 (USD MILLION) 198
TABLE 215 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACOKINETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 216 CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023–2030 (USD MILLION) 200
TABLE 217 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 218 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 219 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 220 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 221 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY REGION, 2023–2030 (USD MILLION) 202
TABLE 222 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACODYNAMIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 223 CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION,
2023–2030 (USD MILLION) 204
TABLE 224 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH,
BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 225 EUROPE: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 226 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION) 205
TABLE 227 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH,
BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 228 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH, BY REGION, 2023–2030 (USD MILLION) 206
TABLE 229 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR BASIC RESEARCH,
BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 230 CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION,
2023–2030 (USD MILLION) 207
TABLE 231 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 232 EUROPE: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 233 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 234 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 235 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES, BY REGION, 2023–2030 (USD MILLION) 209
TABLE 236 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR GENETIC STUDIES,
BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 237 CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 210
TABLE 238 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 239 EUROPE: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 240 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 241 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 242 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 213
TABLE 243 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 244 CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 215
TABLE 245 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2020 VS. 2026 (USD BILLION) 216
TABLE 246 CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 217
TABLE 247 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 217
TABLE 248 EUROPE: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 249 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 250 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 251 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 219
TABLE 252 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 253 CELL-BASED ASSAYS MARKET FOR CROS, BY REGION, 2023–2030 (USD MILLION) 221
TABLE 254 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,
2023–2030 (USD MILLION) 221
TABLE 255 EUROPE: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,
2023–2030 (USD MILLION) 222
TABLE 256 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,
2023–2030 (USD MILLION) 222
TABLE 257 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,
2023–2030 (USD MILLION) 223
TABLE 258 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR CROS, BY REGION,
2023–2030 (USD MILLION) 223
TABLE 259 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR CROS, BY COUNTRY,
2023–2030 (USD MILLION) 223
TABLE 260 CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY REGION, 2023–2030 (USD MILLION) 224
TABLE 261 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 225
TABLE 262 EUROPE: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 225
TABLE 263 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 226
TABLE 264 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 226
TABLE 265 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 226
TABLE 266 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 227
TABLE 267 CELL-BASED ASSAYS MARKET, BY REGION, 2023–2030 (USD MILLION) 229
TABLE 268 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 231
TABLE 269 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 232
TABLE 270 NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 271 NORTH AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 272 NORTH AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 273 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 233
TABLE 274 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 234
TABLE 275 NORTH AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 276 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 234
TABLE 277 US: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 236
TABLE 278 US: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 236
TABLE 279 US: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 280 US: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 237
TABLE 281 US: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 237
TABLE 282 US: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 238
TABLE 283 US: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 284 US: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 238
TABLE 285 CANADA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 239
TABLE 286 CANADA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 287 CANADA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 288 CANADA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 289 CANADA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 241
TABLE 290 CANADA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 241
TABLE 291 CANADA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 241
TABLE 292 CANADA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 242
TABLE 293 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 243
TABLE 294 EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 243
TABLE 295 EUROPE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 296 EUROPE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 297 EUROPE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 298 EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 245
TABLE 299 EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 245
TABLE 300 EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 245
TABLE 301 EUROPE: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 246
TABLE 302 GERMANY: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 247
TABLE 303 GERMANY: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 304 GERMANY: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 305 GERMANY: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 306 GERMANY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 248
TABLE 307 GERMANY: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 249
TABLE 308 GERMANY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 309 GERMANY: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 249
TABLE 310 UK: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 251
TABLE 311 UK: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 251
TABLE 312 UK: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 313 UK: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 314 UK: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 252
TABLE 315 UK: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 253
TABLE 316 UK: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 317 UK: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 253
TABLE 318 FRANCE: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 255
TABLE 319 FRANCE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 320 FRANCE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 321 FRANCE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 322 FRANCE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 256
TABLE 323 FRANCE: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 257
TABLE 324 FRANCE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 257
TABLE 325 FRANCE: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 257
TABLE 326 ITALY: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 258
TABLE 327 ITALY: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 258
TABLE 328 ITALY: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 329 ITALY: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 330 ITALY: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 259
TABLE 331 ITALY: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 260
TABLE 332 ITALY: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 260
TABLE 333 ITALY: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 260
TABLE 334 SPAIN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 261
TABLE 335 SPAIN: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 336 SPAIN: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 337 SPAIN: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 338 SPAIN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 263
TABLE 339 SPAIN: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 263
TABLE 340 SPAIN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 263
TABLE 341 SPAIN: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 264
TABLE 342 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 264
TABLE 343 REST OF EUROPE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 344 REST OF EUROPE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 345 REST OF EUROPE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 266
TABLE 346 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 266
TABLE 347 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 266
TABLE 348 REST OF EUROPE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 349 REST OF EUROPE: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 267
TABLE 350 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 270
TABLE 351 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 270
TABLE 352 ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 353 ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 354 ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 355 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 272
TABLE 356 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 272
TABLE 357 ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 273
TABLE 358 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 273
TABLE 359 CHINA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 274
TABLE 360 CHINA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 274
TABLE 361 CHINA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 362 CHINA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 363 CHINA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 275
TABLE 364 CHINA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 276
TABLE 365 CHINA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 276
TABLE 366 CHINA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 276
TABLE 367 JAPAN: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 277
TABLE 368 JAPAN: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 369 JAPAN: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 370 JAPAN: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 279
TABLE 371 JAPAN: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 279
TABLE 372 JAPAN: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 279
TABLE 373 JAPAN: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 280
TABLE 374 JAPAN: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 280
TABLE 375 INDIA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 281
TABLE 376 INDIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 281
TABLE 377 INDIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 378 INDIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 379 INDIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 282
TABLE 380 INDIA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 283
TABLE 381 INDIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 382 INDIA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 283
TABLE 383 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 284
TABLE 384 AUSTRALIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 385 AUSTRALIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 386 AUSTRALIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 387 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 286
TABLE 388 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 286
TABLE 389 AUSTRALIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 286
TABLE 390 AUSTRALIA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 287
TABLE 391 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 287
TABLE 392 SOUTH KOREA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 288
TABLE 393 SOUTH KOREA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 288
TABLE 394 SOUTH KOREA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 288
TABLE 395 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 289
TABLE 396 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 289
TABLE 397 SOUTH KOREA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 398 SOUTH KOREA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 290
TABLE 399 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 291
TABLE 400 REST OF ASIA PACIFIC: CONSUMABLES MARKET, BY TYPE,
2023–2030 (USD MILLION) 291
TABLE 401 REST OF ASIA PACIFIC: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 292
TABLE 402 REST OF ASIA PACIFIC: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 292
TABLE 403 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 292
TABLE 404 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 293
TABLE 405 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 406 REST OF ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 293
TABLE 407 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 295
TABLE 408 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 295
TABLE 409 LATIN AMERICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 410 LATIN AMERICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 411 LATIN AMERICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 297
TABLE 412 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 297
TABLE 413 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 297
TABLE 414 LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 298
TABLE 415 LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 298
TABLE 416 BRAZIL: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 299
TABLE 417 BRAZIL: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 299
TABLE 418 BRAZIL: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 419 BRAZIL: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 420 BRAZIL: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 300
TABLE 421 BRAZIL: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 301
TABLE 422 BRAZIL: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 301
TABLE 423 BRAZIL: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 301
TABLE 424 MEXICO: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 302
TABLE 425 MEXICO: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 302
TABLE 426 MEXICO: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 303
TABLE 427 MEXICO: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 303
TABLE 428 MEXICO: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 303
TABLE 429 MEXICO: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 304
TABLE 430 MEXICO: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 304
TABLE 431 MEXICO: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 304
TABLE 432 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 305
TABLE 433 REST OF LATIN AMERICA: CONSUMABLES MARKET, BY TYPE,
2023–2030 (USD MILLION) 305
TABLE 434 REST OF LATIN AMERICA: ASSAY KITS MARKET, BY TYPE,
2023–2030 (USD MILLION) 306
TABLE 435 REST OF LATIN AMERICA: CELL LINES MARKET, BY TYPE,
2023–2030 (USD MILLION) 306
TABLE 436 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 306
TABLE 437 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 307
TABLE 438 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 439 REST OF LATIN AMERICA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 307
TABLE 440 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY REGION,
2023–2030 (USD MILLION) 308
TABLE 441 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 309
TABLE 442 MIDDLE EAST: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 309
TABLE 443 MIDDLE EAST: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 310
TABLE 444 MIDDLE EAST: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 310
TABLE 445 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 310
TABLE 446 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 311
TABLE 447 MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 311
TABLE 448 MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 311
TABLE 449 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 312
TABLE 450 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 312
TABLE 451 GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 313
TABLE 452 GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 313
TABLE 453 GCC COUNTRIES: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 314
TABLE 454 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 314
TABLE 455 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 314
TABLE 456 GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 315
TABLE 457 GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 315
TABLE 458 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 316
TABLE 459 SAUDI ARABIA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 316
TABLE 460 SAUDI ARABIA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 317
TABLE 461 SAUDI ARABIA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 317
TABLE 462 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 317
TABLE 463 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 318
TABLE 464 SAUDI ARABIA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 318
TABLE 465 SAUDI ARABIA: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 318
TABLE 466 UAE: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 319
TABLE 467 UAE: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 319
TABLE 468 UAE: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 320
TABLE 469 UAE: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 320
TABLE 470 UAE: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 320
TABLE 471 UAE: CELL-BASED ASSAYS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 321
TABLE 472 UAE: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 321
TABLE 473 UAE: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 321
TABLE 474 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 322
TABLE 475 REST OF GCC COUNTRIES: CONSUMABLES MARKET, BY TYPE,
2023–2030 (USD MILLION) 323
TABLE 476 REST OF GCC COUNTRIES: ASSAY KITS MARKET, BY TYPE,
2023–2030 (USD MILLION) 323
TABLE 477 REST OF GCC COUNTRIES: CELL LINES MARKET, BY TYPE,
2023–2030 (USD MILLION) 324
TABLE 478 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 324
TABLE 479 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 324
TABLE 480 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 325
TABLE 481 REST OF GCC COUNTRIES: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 325
TABLE 482 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY OFFERING,
2023–2030 (USD MILLION) 326
TABLE 483 REST OF MIDDLE EAST: CONSUMABLES MARKET, BY TYPE,
2023–2030 (USD MILLION) 326
TABLE 484 REST OF MIDDLE EAST: ASSAY KITS MARKET, BY TYPE,
2023–2030 (USD MILLION) 327
TABLE 485 REST OF MIDDLE EAST: CELL LINES MARKET, BY TYPE,
2023–2030 (USD MILLION) 327
TABLE 486 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 327
TABLE 487 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 328
TABLE 488 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 328
TABLE 489 REST OF MIDDLE EAST: CELL-BASED ASSAYS MARKET, BY END USER,
2023–2030 (USD MILLION) 328
TABLE 490 AFRICA: CELL-BASED ASSAYS MARKET, BY OFFERING, 2023–2030 (USD MILLION) 330
TABLE 491 AFRICA: CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION) 330
TABLE 492 AFRICA: ASSAY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 331
TABLE 493 AFRICA: CELL LINES MARKET, BY TYPE, 2023–2030 (USD MILLION) 331
TABLE 494 AFRICA: CELL-BASED ASSAYS MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 331
TABLE 495 AFRICA: CELL-BASED ASSAYS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 332
TABLE 496 AFRICA: CELL-BASED ASSAYS MARKET FOR DRUG DISCOVERY APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 332
TABLE 497 AFRICA: CELL-BASED ASSAYS MARKET, BY END USER, 2023–2030 (USD MILLION) 332
TABLE 498 OVERVIEW OF STRATEGIES DEPLOYED BY MANUFACTURING COMPANIES,
JANUARY 2021–APRIL 2025 334
TABLE 499 CELL-BASED ASSAYS MARKET: DEGREE OF COMPETITION 338
TABLE 500 CELL-BASED ASSAYS MARKET: OFFERING FOOTPRINT 343
TABLE 501 CELL-BASED ASSAYS MARKET: TECHNOLOGY FOOTPRINT 344
TABLE 502 CELL-BASED ASSAYS MARKET: APPLICATION FOOTPRINT 345
TABLE 503 CELL-BASED ASSAYS MARKET: REGION FOOTPRINT 346
TABLE 504 CELL-BASED ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 349
TABLE 505 CELL-BASED ASSAYS MARKET: COMPETITIVE BENCHMARKING OF
KEY EMERGING PLAYERS/STARTUPS 351
TABLE 506 CELL-BASED ASSAYS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 354
TABLE 507 CELL-BASED ASSAYS MARKET: DEALS, JANUARY 2021–APRIL 2025 355
TABLE 508 CELL-BASED ASSAYS MARKET: EXPANSIONS, JANUARY 2021–APRIL 2025 356
TABLE 509 DANAHER: COMPANY OVERVIEW 357
TABLE 510 DANAHER: PRODUCTS/SERVICES OFFERED 359
TABLE 511 DANAHER: DEALS, JANUARY 2021–APRIL 2025 361
TABLE 512 DANAHER: EXPANSIONS, JANUARY 2021–APRIL 2025 362
TABLE 513 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 363
TABLE 514 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 364
TABLE 515 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–APRIL 2025 368
TABLE 516 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 369
TABLE 517 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS,
JANUARY 2021–APRIL 2025 369
TABLE 518 MERCK KGAA: COMPANY OVERVIEW 371
TABLE 519 MERCK KGAA: PRODUCTS/SERVICES OFFERED 372
TABLE 520 MERCK KGAA: DEALS, JANUARY 2021–APRIL 2025 375
TABLE 521 MERCK KGAA: EXPANSIONS, JANUARY 2021–APRIL 2025 375
TABLE 522 BD: BUSINESS OVERVIEW 377
TABLE 523 BD: PRODUCTS/SERVICES OFFERED 378
TABLE 524 BD: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025 381
TABLE 525 BD: DEALS, JANUARY 2021–APRIL 2025 381
TABLE 526 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 383
TABLE 527 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED 384
TABLE 528 AGILENT TECHNOLOGIES, INC.: PRODUCTS LAUNCHES,
JANUARY 2021–APRIL 2025 385
TABLE 529 LONZA: COMPANY OVERVIEW 387
TABLE 530 LONZA: PRODUCTS/SERVICES OFFERED 388
TABLE 531 LONZA: DEALS, JANUARY 2021–APRIL 2025 389
TABLE 532 LONZA: EXPANSIONS, JANUARY 2021–APRIL 2025 389
TABLE 533 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 390
TABLE 534 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 391
TABLE 535 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–APRIL 2025 393
TABLE 536 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 394
TABLE 537 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 395
TABLE 538 CHARLES RIVER LABORATORIES: SERVICE LAUNCHES,
JANUARY 2021–APRIL 2025 397
TABLE 539 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–APRIL 2025 397
TABLE 540 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 399
TABLE 541 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 400
TABLE 542 REVVITY: COMPANY OVERVIEW 402
TABLE 543 REVVITY: PRODUCTS/SERVICES OFFERED 403
TABLE 544 REVVITY: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025 405
TABLE 545 SARTORIUS AG: COMPANY OVERVIEW 406
TABLE 546 SARTORIUS AG: PRODUCTS/SERVICES OFFERED 408
TABLE 547 SARTORIUS AG: EXPANSIONS, JANUARY 2021–APRIL 2025 408
TABLE 548 CORNING INCORPORATED: COMPANY OVERVIEW 409
TABLE 549 CORNING INCORPORATED: PRODUCTS/SERVICES OFFERED 410
TABLE 550 PROMEGA CORPORATION: COMPANY OVERVIEW 412
TABLE 551 PROMEGA CORPORATION: PRODUCTS/SERVICES OFFERED 412
TABLE 552 PROMEGA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–APRIL 2025 413
TABLE 553 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 414
TABLE 554 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SERVICES OFFERED 414
TABLE 555 ENZO BIOCHEM INC.: COMPANY OVERVIEW 416
TABLE 556 ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED 417
TABLE 557 ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 419
TABLE 558 CARNA BIOSCIENCES, INC.: BUSINESS OVERVIEW 420
TABLE 559 CARNA BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED 421
TABLE 560 INTERTEK GROUP PLC: COMPANY OVERVIEW 423
TABLE 561 INTERTEK GROUP PLC: PRODUCTS /SERVICES OFFERED 424
TABLE 562 INTERTEK GROUP PLC: EXPANSIONS, JANUARY 2021–APRIL 2025 425
TABLE 563 BICO: COMPANY OVERVIEW 426
TABLE 564 BICO: PRODUCTS/SERVICES OFFERED 427
LIST OF FIGURES
FIGURE 1 CELL-BASED ASSAYS MARKET: SEGMENTS & REGIONS CONSIDERED 40
FIGURE 2 RESEARCH DESIGN 43
FIGURE 3 BREAKDOWN OF PRIMARIES: CELL-BASED ASSAYS MARKET 45
FIGURE 4 CELL-BASED ASSAYS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 46
FIGURE 5 MARKET SIZE ESTIMATION: GLOBAL MARKET ESTIMATION
(BOTTOM-UP APPROACH), 2024 47
FIGURE 6 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION:
REVENUE SHARE ANALYSIS (2024) 47
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 48
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 49
FIGURE 9 CELL-BASED ASSAYS MARKET: CAGR PROJECTIONS 50
FIGURE 10 DATA TRIANGULATION METHODOLOGY 52
FIGURE 11 CELL-BASED ASSAYS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 55
FIGURE 12 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 56
FIGURE 13 CELL-BASED ASSAYS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 56
FIGURE 14 CELL-BASED ASSAYS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CELL-BASED ASSAYS MARKET 58
FIGURE 16 GROWING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET 59
FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2024 60
FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 60
FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT HELD
MAJOR MARKET SHARE IN 2024 61
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH
DURING FORECAST PERIOD 61
FIGURE 21 CELL-BASED ASSAYS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 62
FIGURE 22 AGE-STANDARDIZED RATE (WORLD) PER 100,000 CANCER
INCIDENCES IN BOTH SEXES, 2022 67
FIGURE 23 CELL-BASED ASSAYS MARKET: VALUE CHAIN ANALYSIS 77
FIGURE 24 PRICING ANALYSIS FOR CELL-BASED ASSAY PRODUCTS, 2022–2024 78
FIGURE 25 CELL-BASED ASSAYS MARKET ECOSYSTEM 80
FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 83
FIGURE 27 PATENT APPLICATION IN CELL-BASED ASSAYS MARKET,
JANUARY 2014–APRIL 2025 84
FIGURE 28 CELL-BASED ASSAYS MARKET: PORTER’S FIVE ANALYSIS 92
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
CELL-BASED ASSAY PRODUCTS 94
FIGURE 30 KEY BUYING CRITERIA FOR END USERS 95
FIGURE 31 CELL-BASED ASSAYS MARKET: INVESTMENT AND
FUNDING SCENARIO, 2020-2024 96
FIGURE 32 IMPACT OF AI/GEN AI ON CELL-BASED ASSAYS MARKET 101
FIGURE 33 INSTRUMENTS MARKET (FLOW CYTOMETERS) FOR CELL-BASED ASSAYS,
2023–2030 (THOUSAND UNITS) 162
FIGURE 34 WORLDWIDE TOTAL PHARMACEUTICAL R&D SPEND, 2021–2028 216
FIGURE 35 NORTH AMERICA: CELL-BASED ASSAYS MARKET SNAPSHOT 231
FIGURE 36 ASIA PACIFIC: CELL-BASED ASSAYS MARKET SNAPSHOT 269
FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN CELL-BASED ASSAYS
MARKET (2020–2024) 337
FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL-BASED
ASSAYS MARKET (2024) 338
FIGURE 39 CELL-BASED ASSAYS MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2024 341
FIGURE 40 CELL-BASED ASSAYS MARKET: COMPANY FOOTPRINT 342
FIGURE 41 CELL-BASED ASSAYS MARKET: COMPANY EVALUATION MATRIX, (STARTUPS/SMES), 2024 348
FIGURE 42 EV/EBITDA OF KEY VENDORS 352
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 352
FIGURE 44 CELL-BASED ASSAYS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 353
FIGURE 45 DANAHER: COMPANY SNAPSHOT (2024) 358
FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 364
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2024) 372
FIGURE 48 BD: COMPANY SNAPSHOT (2024) 378
FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 384
FIGURE 50 LONZA: COMPANY SNAPSHOT (2024) 388
FIGURE 51 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 391
FIGURE 52 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024) 395
FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 400
FIGURE 54 REVVITY: COMPANY SNAPSHOT (2024) 403
FIGURE 55 SARTORIUS AG: COMPANY SNAPSHOT (2024) 407
FIGURE 56 CORNING INCORPORATED: COMPANY SNAPSHOT (2024) 410
FIGURE 57 ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2024) 416
FIGURE 58 CARNA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024) 421
FIGURE 59 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2024) 424
FIGURE 60 BICO: COMPANY SNAPSHOT (2024) 427
MarketsandMarkets(マーケッツアンドマーケッツ)は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間~12時間以内(営業日基準)にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
シングルユーザ | コーポレート |
USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨(定価)を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料(ハンドリングチャージ)無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内(関連会社除く)5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100%持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内(営業日基準)
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- UV安定剤市場 – 2030年までの世界予測 2025-05-16
- 産業用通信市場 – 2030年までの世界予測 2025-05-16
- 経腸栄養装置市場 – 2030年までの世界予測 2025-05-15
- データセンターGPU市場 – 2030年までの世界予測 2025-05-15
- ステンレス鋼シームレスパイプ市場 – 2030年までの世界予測 2025-05-15